Most Read

B7451012 was a randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of two doses (100mg and 200mg once daily) of abrocitinib monotherapy over 12

The results were presented by Eric D. Donnenfeld, M.D., last week at the 2019 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators (ASCRS•ASOA)

With Daiichi Sankyo’s first commercial sale of MINNEBRO, Exelixis will receive an associated $20 million milestone payment from Daiichi Sankyo under the terms of the companies’ collaboration agreement.

The results demonstrated Gilenya 0.5mg’s superior efficacy over glatiramer acetate 20mg in reducing the annualized relapse rate (ARR), a key measure of disease activity, with a 40.7% relative

It is the company’s investigational 15-valent pneumococcal conjugate vaccine, as compared to the currently available 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants 6-12 weeks of age. In

Ligand will pay $12 million to Novan and in return will be entitled to receive a tiered royalty of 7% to 10%, as well as up to $20

Pear Therapeutics is developing Pear-006 in collaboration with Novartis under the terms of an agreement announced in March 2018. Clinicians estimate that between 35-50% of people with MS

The primary endpoint of the trial is progression-free survival, and the secondary endpoints are overall survival and objective response rate. “Clinical observations suggest cabozantinib promotes an immune-permissive environment,

KALYDECO is already approved in the U.S., Canada and EU for the treatment of CF in patients ages 12 months and older. “Today’s approval for KALYDECO allows physicians